News | Oncology Information Management Systems (OIMS) | June 01, 2020

RaySearch Enters Into Interoperability Agreement with Varian

RaySearch Laboratories AB and Varian Medical Systems have entered into an interoperability agreement that will allow the RayCare oncology information system to connect to Varian TrueBeam linear accelerators

June 1, 2020 — RaySearch Laboratories AB and Varian Medical Systems have entered into an interoperability agreement that will allow the RayCare oncology information system to connect to Varian TrueBeam linear accelerators.

The ability to schedule radiation treatments and keep track of the treatment progress is a key functionality in an oncology information system. Under the announced agreement, a dedicated interface has been defined which allows RayCare and Varian TrueBeam to communicate the data necessary for an integrated workflow. This means that clinics will be able to use RayCare to manage all clinical activities around their Varian TrueBeam accelerators.

The development of the interface is already ongoing, and the target is to release it before the end of 2020. Commercial availability will be subject to regulatory clearance in some markets.

Johan Löf, founder and CEO at RaySearch, said: “We are constantly working to add support for more treatment machines in RayCare, and I’m very happy that we have now entered into this agreement. Interoperability with Varian TrueBeam will significantly expand the market potential for RayCare and improve the workflow for our existing customers.”

For more information: www.raysearchlabs.com

Related Content

At the American Association of Physicists in Medicine (AAPM) 2019 meeting, new artificial intelligence (AI) software to assist with radiotherapy treatment planning systems was highlighted. The goal of the AI-based systems is to save staff time, while still allowing clinicians to do the final patient review. 
Feature | Treatment Planning | July 08, 2020 | By Melinda Taschetta-Millane
At the American Association of Physicists in Medicine (AAPM) 201
Changes outlined in new draft U.S. Preventive Services Task Force (USPSTF) lung cancer screening recommendations will greatly increase the number of Americans eligible for screening and help medical providers save thousands more lives each year.

Image courtesy of Cerner

News | Lung Cancer | July 08, 2020
July 8, 2020 — Changes outlined in new draft U.S.
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

News | Pediatric Imaging | June 29, 2020
June 29, 2020 — A type of smart magnetic r...
Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020.

Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020. Courtesy of Nature Medicine

News | Coronavirus (COVID-19) | June 25, 2020
June 25, 2020 — The characterization of COVID-19